Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
QuintilesIMS
McKesson
Teva
Daiichi Sankyo
US Department of Justice

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,452,874

« Back to Dashboard

Which drugs does patent 7,452,874 protect, and when does it expire?

Patent 7,452,874 protects PROMACTA KIT and PROMACTA and is included in two NDAs.

Protection for PROMACTA KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-two patent family members in twenty-eight countries.

Summary for Patent: 7,452,874
Title:Thrombopoietin mimetics
Abstract:Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.
Inventor(s): Duffy; Kevin J. (Collegeville, PA), Luengo; Juan I. (Collegeville, PA), Shaw; Antony N. (Collegeville, PA), Wiggall; Kenneth (Collegeville, PA)
Assignee: SmithKline Beecham Corp. (Philadelphia, PA)
Application Number:11/650,838
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,452,874
Patent Claim Types:
see list of patent claims
Compound; Composition; Process;

Drugs Protected by US Patent 7,452,874

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp PROMACTA KIT eltrombopag olamine FOR SUSPENSION;ORAL 207027-001 Aug 24, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-004 Oct 20, 2011 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-001 Nov 20, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-002 Nov 20, 2008 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-003 Sep 8, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Army
Deloitte
McKinsey
Fuji
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.